Kadem Al-Lamee

Kadem Al-Lamee, CEO, Arterius Limited, was a co-founder of PolyBioMed Limited in 1996, serving as Technical Director before becoming Managing Director in 2001, when PolyBioMed was acquired by Lombard Medical Technologies. PolyBioMed was recently purchased by Bayer Materials Science. Dr Al-Lamee was integral to the development of the business throughout its history, including strategic development, fund-raising, technical development and the establishment of its intellectual property portfolio. Previously he was Principal Scientist in polymer chemistry for Innovative Technologies plc, managing research and development programmes in areas including wound dressings and coated urinary catheters. Dr Al-Lamee has extensive research and teaching experience with an MSc and PhD in Polymer Chemistry from the University of Liverpool. He has over 30 years experience in Biomaterials and Medical Devices, has published over 50 papers in international journals and holds 25 granted patents/patent applications. Dr Al-Lamee’s main interests are biomaterials, surface modifications and the coating of materials commonly used in medical devices, drug delivery systems, hydrogels for medical applications, cardiovascular devices, wound-care products, urology and tissue engineering devices. He has been successfully awarded many grants from the UK’s DTI, the Innovate UK, Yorkshire Forward, and European Commission for the research and development of healthcare projects.